Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression ...

A new study from the Hong Kong Children's Hospital reveals critical insights into the infection risks associated with ...

Med is proud to announce a strategic partnership with an FDA-approved laboratory in the field of regenerative medicine. This ...

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Immunocompromised patients undergoing hematopoietic stem cell transplants (HSCTs) who have a reported penicillin allergy should be evaluated as the allergy label limits access to preferred antibiotics ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.